STEP 2 Trial: Semaglutide in Type 2 Diabetes and What the Full STEP Program Reveals

What Was the STEP 2 Trial and Why Does It Matter?

STEP 2 was a phase 3, double-blind, randomized controlled trial that enrolled 1,210 adults with both overweight or obesity and type 2 diabetes, testing whether semaglutide 2.4 mg weekly could produce clinically meaningful weight loss in a population where GLP-1 agonists already carry an A-level evidence base for glycemic control. The trial ran for 68 weeks with a 16-week dose-escalation period. It answered a question that STEP 1 left open: does the metabolic dysregulation of type 2 diabetes blunt semaglutide's weight-loss effect?

The short answer is yes, but only partially. Participants in STEP 2 lost a mean 9.6% of body weight on the 2.4 mg dose, compared with 3.4% on placebo, a difference of 6.2 percentage points [1]. The 14.9% seen in STEP 1's non-diabetic cohort remains higher, but 9.6% still clears the FDA's 5% threshold for meaningful clinical weight loss with statistical separation from placebo at P<0.001. The trial also tested a 1.0 mg semaglutide dose (the approved glycemic dose in Ozempic), which produced only 7.0% weight loss, reinforcing the dose-response relationship that justifies the higher 2.4 mg formulation used in Wegovy [1].

Hemoglobin A1c fell by 1.6 percentage points in the 2.4 mg arm versus 0.4 points in placebo, which confirms the dual metabolic benefit relevant to any clinician prescribing semaglutide in a patient with T2D. The Lancet published these results in March 2021, and the FDA cited STEP 2 as part of the supporting package when it approved Wegovy two months later [2].

STEP 1: The Key Weight-Loss Data in Non-Diabetic Adults

STEP 1 enrolled 1,961 adults with obesity or overweight plus at least one weight-related complication (but without type 2 diabetes) and remains the most-cited trial in semaglutide prescribing discussions. At 68 weeks, the semaglutide 2.4 mg group lost a mean 14.9% of body weight versus 2.4% on placebo, a difference of 12.4 percentage points [3]. About 86.4% of participants on semaglutide achieved at least 5% weight loss, 69.1% achieved at least 10%, and 50.5% achieved at least 15%.

Those responder rates matter clinically. Weight loss of 10% or more produces measurable reductions in blood pressure, sleep apnea severity, and lipid panel values according to established cardiovascular risk models. The NEJM published STEP 1 results in February 2021 alongside STEP 2, giving the FDA a paired dataset covering patients with and without diabetes [3].

Gastrointestinal adverse events drove the most discontinuations: nausea affected 44.2% of the semaglutide group versus 16.0% of placebo, though most events were mild-to-moderate and peaked during the escalation phase. Serious adverse events were similar between arms at roughly 9 to 10%, and no new safety signals emerged beyond the existing Ozempic label [3].

STEP 3: Combining Semaglutide with Intensive Behavioral Therapy

STEP 3 asked whether adding structured behavioral support on top of semaglutide 2.4 mg could push weight loss beyond what drug alone achieves. The trial enrolled 611 adults without diabetes and assigned them to semaglutide plus intensive behavioral therapy (IBT, defined as 30 counseling visits over 68 weeks) versus placebo plus IBT [4].

Weight loss at 68 weeks reached 16.0% in the semaglutide-plus-IBT arm versus 5.7% in placebo-plus-IBT [4]. The takeaway for clinicians is that IBT adds roughly 1 percentage point over semaglutide alone when comparing STEP 3 to STEP 1's 14.9%, a modest but real increment.

JAMA published STEP 3 in April 2021. The authors noted that the behavioral program used in the trial exceeds what most real-world telehealth platforms offer, so the marginal benefit in clinical practice may be smaller. Still, the FDA Wegovy label references these findings to support co-prescribing lifestyle intervention alongside the drug [5].

STEP 5: Two-Year Durability of Semaglutide 2.4 mg

A common clinician question is whether weight loss on semaglutide persists beyond the one-year mark or whether a plateau erodes benefit over time. STEP 5 addressed this directly. The trial enrolled 304 adults without diabetes and randomized them 2:1 to semaglutide 2.4 mg or placebo for 104 weeks, roughly double the duration of STEP 1 through 3.

Mean weight loss at week 104 was 15.2% on semaglutide versus 2.6% on placebo [6]. Weight loss continued to deepen from week 20 to roughly week 60, then stabilized, and participants maintained that lower weight through week 104 without rebound. No new safety signals emerged at the two-year mark [6].

The durability data matter for payer and prescriber conversations. Obesity is a chronic condition requiring long-term treatment just as hypertension does, and STEP 5 provides the two-year dataset that supports indefinite prescribing rather than a time-limited course.

STEP 8: Semaglutide 2.4 mg Versus Liraglutide 3.0 mg Head-to-Head

Before tirzepatide's approval, the most clinically relevant comparison in GLP-1 prescribing was semaglutide 2.4 mg (Wegovy) against liraglutide 3.0 mg (Saxenda). STEP 8 was the first randomized head-to-head trial to answer that question directly, enrolling 338 adults with obesity or overweight without diabetes [7].

At 68 weeks, semaglutide produced 15.8% mean weight loss versus 6.4% for liraglutide, a difference of 9.4 percentage points [7]. The proportion achieving at least 10% weight loss was 70.9% on semaglutide versus 25.6% on liraglutide. JAMA published these results in January 2022.

Gastrointestinal side-effect profiles were similar in character but liraglutide's daily injection schedule was associated with slightly higher discontinuation due to injection-site reactions. From a shared decision-making standpoint, STEP 8 gives prescribers a hard number: switching a patient from liraglutide to semaglutide could approximately double their weight loss outcome on a population level [7].

How the STEP Program Compares to SURMOUNT (Tirzepatide)

Tirzepatide (Zepbound, Mounjaro) is a dual GIP/GLP-1 receptor agonist that entered phase 3 trials after the STEP program was complete, and its SURMOUNT results raised the ceiling on expected weight loss.

In SURMOUNT-1, tirzepatide 15 mg produced 20.9% mean body-weight loss at 72 weeks in adults without diabetes (N=2,539), compared with 3.1% placebo [8]. That exceeds STEP 1's 14.9% by about 6 percentage points. In SURMOUNT-2, which enrolled adults with type 2 diabetes (the equivalent of STEP 2's population), tirzepatide 15 mg produced 14.7% weight loss versus 3.3% placebo [9]. STEP 2's semaglutide result in the same population was 9.6%.

That 5-point gap between SURMOUNT-2 and STEP 2 is the number most often cited in formulary discussions and telehealth prescribing algorithms. Neither trial was head-to-head, so cross-trial comparisons carry the usual caveats about baseline differences. A direct randomized comparison has not yet been published as of this article's review date.

SURMOUNT-3 examined tirzepatide after a 12-week intensive lifestyle run-in and found 18.4% weight loss at 72 weeks in those who received drug versus 2.5% placebo [10]. SURMOUNT-4 addressed maintenance: participants who had already lost weight on tirzepatide were randomized at week 36 to continue drug or switch to placebo. Those who continued lost an additional 5.5%, while those who withdrew regained 14.8% of body weight by week 88 [11]. Parallel data from the STEP program's open-label extension showed a similar rebound pattern, reinforcing that both drugs require continuous use to sustain benefit.

Prescribing Semaglutide 2.4 mg: Eligibility, Dosing, and Monitoring

The Wegovy FDA label approves semaglutide 2.4 mg for adults with a BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or type 2 diabetes [5]. The same label extends approval to adolescents aged 12 and older following STEP TEENS data.

Dosing follows a 16-week escalation schedule: 0.25 mg weekly for weeks 1 through 4 to 0.5 mg for weeks 5 through 8 to 1.0 mg for weeks 9 through 12 to 1.7 mg for weeks 13 through 16, then 2.4 mg from week 17 onward [5]. Patients who do not tolerate escalation may pause at any intermediate dose for an additional four weeks before attempting the next step up.

The AACE/ACE obesity clinical practice guidelines state that pharmacotherapy should be considered for patients who do not achieve sufficient weight loss with lifestyle intervention alone, and that agents with cardiovascular outcome data should be preferred in patients with established cardiovascular disease [12]. Semaglutide 2.4 mg now carries cardiovascular outcome data from SELECT (N=17,604), which showed a 20% relative risk reduction in major adverse cardiovascular events in adults with obesity and prior cardiovascular disease but without diabetes [13]. The SELECT trial's primary endpoint HR was 0.80 (95% CI 0.72 to 0.90, P<0.001) [13].

Monitoring after initiation should include weight at each visit, fasting glucose or A1c at 3-month intervals in patients with prediabetes or T2D, and a review of GI tolerance at the first follow-up four weeks after each dose increase. Thyroid C-cell tumors are a boxed-warning contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN 2 [5].

The HealthRX clinical team applies the following tiered prescribing framework based on STEP and SURMOUNT evidence:

Tier 1 (start here): Semaglutide 2.4 mg for patients without T2D and BMI 30 or above, or BMI 27 with one comorbidity. Expected 15-week response check: if less than 4% weight loss by week 16, reassess adherence before escalating to tirzepatide.

Tier 2 (T2D population): Tirzepatide 10 or 15 mg is preferred over semaglutide 2.4 mg when A1c control is also a goal, given SURMOUNT-2's superior weight and glycemic outcomes versus STEP 2's semaglutide data. If cost or coverage prohibits tirzepatide, semaglutide 2.4 mg at full dose remains effective and guideline-supported.

Tier 3 (prior cardiovascular event, no T2D): Semaglutide 2.4 mg is the evidence-backed first choice given SELECT's MACE data; tirzepatide lacks an equivalent cardiovascular outcomes trial as of early 2025.

Understanding Why Type 2 Diabetes Reduces GLP-1 Weight-Loss Response

The 5-percentage-point gap between STEP 1 (14.9%) and STEP 2 (9.6%) is not coincidental. Several mechanisms contribute. Beta-cell dysfunction in T2D blunts the incretin-amplified insulin response that partly mediates GLP-1's satiety effect. Patients with T2D frequently take sulfonylureas or insulin, which can partially counter weight loss through anabolic signaling. Baseline A1c above 8% is associated with higher caloric intake patterns that take longer to remodel.

A secondary analysis of STEP 2 data found that participants who achieved A1c normalization (below 5.7%) at week 68 lost proportionally more weight than those who remained in the diabetic range, suggesting that glycemic improvement and weight loss are bidirectionally reinforcing in this population [1]. That mechanistic detail helps explain why SURMOUNT-2's tirzepatide outperformed STEP 2's semaglutide: dual GIP/GLP-1 activation provides additional beta-cell support that may reduce the blunting effect of T2D on appetite suppression.

Safety Signals Across the STEP Program

All five STEP trials used a consistent safety-monitoring framework, allowing a cross-trial signal assessment rarely possible in drug development.

Nausea was the most common adverse event across all arms, ranging from 38% to 44% on semaglutide versus 12% to 18% on placebo. Rates were highest in the first 12 weeks of each trial, corresponding to the dose-escalation phase, and declined sharply after reaching the maintenance dose [3][6]. Vomiting occurred in 24 to 26% of semaglutide participants in STEP 1 and STEP 3.

Gallbladder disorders (primarily cholelithiasis) were elevated in semaglutide arms: 2.6% versus 1.2% placebo in STEP 1 [3]. The mechanism is reduced gallbladder motility combined with rapid weight loss. Clinicians should ask about biliary symptoms at each visit.

Acute pancreatitis rates were low and balanced between arms in STEP 1 and STEP 2 (fewer than 0.3% in each). The SELECT trial (N=17,604, longer duration) showed no statistically significant increase in pancreatitis versus placebo [13]. Pulse rate increased by a mean 2 to 3 beats per minute on semaglutide, consistent with the known class effect, with no associated increase in arrhythmia events [3][6].